CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 1,541 target
Drug / intervention
Gene-modified (GM) T cell therapygenetic
Likely dose
Not stated in record
Key inclusion· 3
  • ✓Previous gene-modified T-cell infusion in Celgene, Juno, BMS affiliate, or alliance partner trial
  • ✓Discontinued or completed post-treatment follow-up in parent treatment protocol
  • ✓Must provide informed consent
Key exclusion· 0

None specified.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03435796
NCT03435796Phase 2RecruitingHigh Momentum
Long Recruiting
CompareCT.gov

Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells

Celgene·interventional·Posted Feb 19, 2018·Updated Jun 2, 2026

In Brief

A Phase 2 clinical trial evaluating Gene-modified (GM) T cell therapy for Neoplasms. Currently recruiting, targeting 1,541 participants across 205 sites in 20 countries.

Signals

Enrolling ahead of pace

Detailed Summary

This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms
CountriesAustralia, Austria, Belgium, Canada, Finland, France, Germany, Israel, Italy, Japan, Netherlands, Norway, Poland, Romania, South Korea, Spain, Sweden, Switzerland, United Kingdom, United States
Collaborators--

Timeline

Phase 2Recruiting
20182019202020212022202320242025202620272028202920302031203220332034203520362037
First PostedFeb 19, 2018
Enrollment StartJul 19, 2018
Primary CompletionNov 30, 2036
TodayJul 2, 2026
Enrollment to primary: 18.4 yearsPosted 8.4 years agoPrimary completion in 10.4 years

Arms & Interventions

Participants exposed to Gene-modified (GM) T cell therapyother

Genetic: Gene-modified (GM) T cell therapy

Interventions

Gene-modified (GM) T cell therapygenetic

No investigational product will be administered